Candel Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
CADL$9.35-1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (Unaudited)
Condensed Consolidated Statements of Cash Flows
(In thousands)
| SIX MONTHS ENDEDJUNE 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash Flows from Operating Activities: | ||
| Net income (loss) | $(47,766) | $2,583 |
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||
| Depreciation expense | 320 | 487 |
| Impairment of fixed assets | — | 82 |
| Loss on the disposal of fixed assets | — | 11 |
| Non-cash stock compensation expense | 4,310 | 1,364 |
| Non-cash lease expense | 186 | 151 |
| Non-cash interest expense | 79 | 69 |
| Change in fair value of warrant liabilities | 4,635 | (20,572) |
| Accretion of debt discount | 622 | 76 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (1,068) | (1,771) |
| Other assets | (11) | 18 |
| Accounts payable | 4,082 | 1,513 |
| Accrued expenses | (346) | (1,243) |
| Deferred income | (44) | — |
| Lease liability | (218) | (275) |
| Net cash used in operating activities | (35,219) | (17,507) |
| Cash Flows from Investing Activities: | ||
| Purchase of fixed assets | (744) | (34) |
| Net cash used in investing activities | (744) | (34) |
| Cash Flows from Financing Activities: | ||
| Proceeds from option exercises | 59 | 492 |
| Proceeds from issuance of common stock in public offering, net of issuance costs | 93,488 | — |
| Proceeds from issuance of common stock in registered direct offering | — | 15,044 |
| Proceeds from sale of common stock through at-the-market offerings, net of issuance costs | 24,250 | 5,038 |
| Principal payments on term loan | — | (5,000) |
| Net cash provided by financing activities | 117,797 | 15,574 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 81,834 | (1,967) |
| Cash, cash equivalents and restricted cash at beginning of period | 120,147 | 102,920 |
| Cash, cash equivalents and restricted cash at end of period | $201,981 | $100,953 |
| Supplemental cash flow information: | ||
| Cash paid for interest | $2,441 | $444 |
| Supplemental disclosures of non-cash information: | ||
| Issuance costs in accounts payable and accrued expenses | $— | $638 |
| Capital expenditures in accounts payable and accrued expenses | $68 | $13 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.